Vera Therapeutics, Inc. (VERA)

Market Cap	1.36B
Revenue (ttm)	n/a
Net Income (ttm)	-152.15M
Shares Out	63.75M
EPS (ttm)	-2.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	661,243
Open	21.48
Previous Close	21.24
Day's Range	21.08 - 21.50
52-Week Range	18.53 - 51.61
Beta	1.28
Analysts	Buy
Price Target	65.50 (+209.11%)
Earnings Date	May 8, 2025

About VERA

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company’s lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 14, 2021
• Employees: 112
• Stock Exchange: NASDAQ
• Ticker Symbol: VERA
• Website: https://veratx.com

Analyst Forecast

According to 8 analysts, the average rating for VERA stock is "Buy." The 12-month stock price forecast is $65.5, which is an increase of 209.11% from the latest price.

Price Target

$65.5

(209.11% upside)

Analyst Consensus: Buy